S&P 500 Industrials Sector SEC Filings — May 19, 2026

19-05-2026

Next Bridge Hydrocarbons, Inc. filed an amended S-1 registration statement with the SEC on May 18, 2026, for a proposed public offering. The filing includes a Placement Agent Agreement with Roth Capital Partners, LLC dated April 30, 2026, and references numerous amendments to loan and promissory note agreements with Gregory McCabe, the Chairman and CEO, indicating ongoing related-party financing. The company has a history of debt restructurings and has not yet provided financial statement schedules, suggesting limited operational scale.

• · The registration statement references a Series A Redeemable Preferred Stock certificate filed August 26, 2025, and a Series C Preferred Stock certificate correction filed January 20, 2026.
• · The company has entered into multiple participation agreements with Magnetar Exploration L.P. for the Valentine and Panther prospects, dated March 27, 2024.
• · A Contribution Agreement with Wildcat Partners SPV, LLC was signed on March 27, 2024.
• · The filing includes a Subordination Agreement and an Assignment of Net Profits Interest and Irrevocable Option to Convert to Working Interest, both dated August 26, 2025.
• · The company's independent registered public accountant is M&K CPAS, PLLC.
• · The filing was signed in Fort Worth, Texas on May 18, 2026.

19-05-2026

Regional Management Corp. granted LTIP awards to NEOs on May 13, 2026, including PRSUs and restricted stock, with CEO Lakhbir Lamba receiving the largest grants ($1.25M each). Stockholders re-approved the amended 2024 Long-Term Incentive Plan, increasing authorized shares from 381,000 to 813,014. All nine director nominees were elected, and the advisory vote on executive compensation passed with 90.8% support, though the LTIP re-approval saw 16.3% against votes.

• · PRSUs can be earned from 0% to 170% of target based on TSR ranking vs. custom comparator group and pre-provision return on assets targets over a three-year performance period (May 13, 2026 – May 13, 2029).
• · PRSUs require continued employment through December 31, 2028, and shares are subject to an additional one-year holding period, distributed no earlier than December 31, 2029.
• · Restricted stock vests in three equal tranches on December 31, 2026, 2027, and 2028, subject to continued employment.
• · The 2024 Plan amendment also increased the maximum number of shares for incentive stock options from 381,000 to 813,014, revised the non-employee director award limit to include cash-denominated awards, and eliminated installment vesting during the one-year minimum vesting period for awards granted on or after May 14, 2026.
• · Ratification of Deloitte & Touche LLP as independent auditor passed with 7,897,395 For, 19,961 Against, 103,466 Abstain.
• · Advisory vote on NEO compensation: 5,990,738 For, 606,648 Against, 38,492 Abstain, 1,384,944 Broker Non-Votes.

19-05-2026

Red Robin Gourmet Burgers Inc. reported total revenues of $378.3M for the 16 weeks ended April 19, 2026, down 3.6% from $392.4M in the prior-year period, driven by a 3.8% decline in restaurant revenue. The company swung to a net loss of $2.2M (or -$0.12 per diluted share) from net income of $1.2M ($0.07 per diluted share) a year ago, as operating income fell 39.4% to $5.5M. However, cash and cash equivalents increased to $24.3M from $19.9M at year-end 2025, and operating cash flow remained positive at $7.0M, though down sharply from $19.6M in the prior period.

• · Cost of sales decreased 1.6% YoY to $86.6M, while labor costs fell 7.5% to $132.4M.
• · General and administrative expenses declined 14.4% to $23.1M, partly due to lower stock-based compensation ($1.7M vs $2.6M).
• · Selling expenses increased 41.3% to $13.2M from $9.4M.
• · Other charges, net rose to $4.8M from $0.7M, including $0.5M in asset impairment.
• · Interest expense decreased 3.6% to $7.8M.
• · Net cash used in investing activities was $6.7M, down from $6.4M, with capital expenditures of $6.7M.
• · Financing activities provided $4.1M, primarily from $5.5M in net borrowings on the revolving credit facility.
• · Unearned revenue fell 38.3% to $16.8M from $27.3M at year-end 2025, driven by a decline in unearned gift card revenue.
• · Total assets decreased 3.5% to $543.8M from $563.5M at year-end 2025.
• · Stockholders' deficit widened slightly to $106.7M from $106.3M.

19-05-2026

Moving iMage Technologies (MITQ) reported Q3 FY2026 revenue of $3.39M, down 4.9% YoY from $3.57M, due to seasonally slow customer activity. However, gross margin improved to 34.8% from 29.8%, and net loss narrowed to ($122k) from ($240k). The company highlighted initial traction from its DCS loudspeaker line ($460k sales) and provided Q4 revenue guidance of ~$5.3M.

• · Nine-month FY2026 revenue was $12.77M vs $12.26M in prior year period.
• · Nine-month FY2026 net loss was ($1k) vs ($792k) in prior year period.
• · Cash used in operating activities for nine months FY2026 was ($3.30M) vs $91k provided in prior year period.
• · DCS sales in Q2 FY2026 were $22k, compared to $460k in Q3 FY2026.
• · Q4 FY2026 gross margin guidance is 25%-30%, up from 20%-25% in Q4 FY2025.
• · Company has zero debt.
• · Accounts receivable increased to $1.63M from $1.46M at June 30, 2025.
• · Inventories increased to $3.18M from $2.07M at June 30, 2025.
• · Customer deposits decreased to $270k from $1.10M at June 30, 2025.
• · Accumulated deficit remained nearly unchanged at ($7.205M) vs ($7.204M) at June 30, 2025.

19-05-2026

GeoVax Labs, Inc. announced a $3 million private placement financing priced at-the-market under Nasdaq rules, with gross proceeds of approximately $3 million from the sale of 2,027,027 shares of common stock (or equivalents) and accompanying Series A and Series B warrants. The company plans to use net proceeds for working capital and general corporate purposes, while its priority program GEO-MVA is advancing toward a pivotal Phase 3 clinical trial in the second half of 2026. However, the financing is dilutive to existing shareholders, and the company remains a clinical-stage biotech with no approved products, facing significant development and regulatory risks.

• · The offering is expected to close on or about May 19, 2026.
• · The securities are being sold in reliance on an exemption under Section 4(a)(2) of the Securities Act and/or Regulation D.
• · GeoVax has agreed to file a registration statement with the SEC covering the resale of the shares and underlying shares.
• · GeoVax's priority program GEO-MVA is advancing under an expedited regulatory pathway with plans for a pivotal Phase 3 trial in H2 2026.
• · Gedeptin has completed a Phase 1/2 trial in advanced head and neck cancer and is being advanced into combination strategies.
• · GEO-CM04S1 is a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised populations.

19-05-2026

Educational Development Corp (EDUC) reported a net profit of $2.3M for FY2026, a significant turnaround from a net loss of $5.3M in FY2025. Net revenues declined 33% to $22.9M, driven by a 35% drop in its PaperPie direct sales division, where active Brand Partners fell 53% to 5,800. However, profitability improved due to a large $12.2M gain on asset sales, lower operating expenses, and reduced interest costs.

• · EPS: Basic and diluted earnings per share were $0.27 in FY2026, compared to a loss of ($0.63) in FY2025.
• · Weighted average basic shares outstanding: 8,563,491 in FY2026 vs. 8,348,971 in FY2025.
• · Gross margin decreased 35.3% to $13.6M, but gross margin percentage improved slightly to 59.4% from 61.5%.
• · Interest expense decreased 32.4% to $1.5M from $2.2M.
• · Operating cash flow not provided, but cash and cash equivalents increased to $1.1M from $0.4M.
• · Line of credit was fully paid down to $0 from $4.2M; current maturities of long-term debt reduced to $0 from $26.7M.
• · Assets held for sale dropped to $0.6M from $19.3M, indicating a significant asset disposal/sale during the year.
• · Deferred income tax asset went to $0 from $2.5M.
• · Operating lease right-of-use assets increased to $6.7M from $1.1M, while operating lease liabilities (current + noncurrent) increased to $6.7M from $1.1M.
• · Inventory (net) total (current + noncurrent) decreased to $37.7M from $44.7M.
• · Retained earnings increased to $39.6M from $37.3M due to FY2026 profit.
• · No dividends were paid in either period.

19-05-2026

Dine Brands Global, Inc. held its 2026 Annual Meeting on May 14, 2026, where all nine director nominees were elected, and stockholders ratified KPMG LLP as independent auditor for fiscal 2026. While the advisory vote on executive compensation passed, it received significant opposition (1,131,217 against, 490,425 abstain), and a stockholder proposal to lower the special meeting ownership threshold to 15% was rejected.

• · All nine director nominees received majority support, with the lowest 'For' votes being 7,060,729 for Lilian C. Tomovich.
• · Ratification of KPMG LLP as auditor passed overwhelmingly with 9,728,152 votes for and only 59,013 against.
• · The advisory vote on executive compensation (Proposal Three) had 6,168,102 for, 1,131,217 against, and 490,425 abstain, indicating notable shareholder dissent.
• · Proposal Four (advisory right to call special meeting at 25% threshold) passed with 5,130,454 for and 2,088,982 against.
• · Proposal Five (stockholder proposal for 15% threshold) failed with 3,300,205 for and 4,172,782 against.
• · Broker non-votes were 2,426,174 on all proposals except the ratification of auditor (which had no broker non-votes).

19-05-2026

Innovative Digital Investors Acquisition Corp. (a blank check company) filed Amendment No. 6 to its S-1 registration statement on May 19, 2026, for an initial public offering of 20,000,000 units at $10.00 per unit, each consisting of one share of common stock and three-quarters of one redeemable warrant. The company intends to focus on a business combination target in the financial services industry in North America and must complete an initial business combination within 18 months (with possible extensions up to 24 months) or redeem all public shares. The filing also details a private placement of 425,000 private units and 1,000,000 Sponsor OTM Warrants for an aggregate purchase price of $4,350,000.

• · The company is a blank check company (SPAC) with no specific business combination target selected and no substantive discussions with any target.
• · Each whole warrant entitles the holder to purchase one share of common stock at $11.50 per share, subject to adjustment.
• · Warrants become exercisable on the later of 30 days after the initial business combination and 12 months from the closing of the offering, and expire five years after the business combination.
• · Sponsor OTM Warrants have an exercise price of $15.00 per share and expire ten years after the business combination.
• · The company has applied to list units on the Nasdaq Global Market under the symbol 'IDIAU', with common stock and warrants expected to trade under 'IDIA' and 'IDIA W' respectively, beginning separate trading on the 52nd day after the prospectus date.
• · The company is an emerging growth company and will be subject to reduced public company reporting requirements.
• · There are potential conflicts of interest as officers and directors may have fiduciary duties to other entities and the low price paid for founder shares creates an incentive to complete a transaction even if it is unprofitable for public stockholders.
• · If the initial business combination is not completed within the completion window, founder shares and private warrants may expire worthless.

19-05-2026

Rovida Investment Management Ltd filed its quarterly 13F-HR for the period ending March 31, 2026, reporting total disclosed holdings of approximately $797.3 million across 17 equity positions. The portfolio shows significant concentration in Kratos Defense & Security Solutions ($125.0M), Nebius Group N.V. ($196.3M), and Boeing ($122.8M), while also including positions in Alibaba, NVIDIA, and Freeport-McMoRan. No period-over-period comparison data is available in this initial filing.

• · The filing is a 13F-HR for the quarter ended March 31, 2026, filed on May 19, 2026.
• · All 17 positions are held with sole voting and dispositive power; no shared or non-dispositive holdings reported.
• · The largest position by value is Nebius Group N.V. Class A at $196.3M (1,893,647 shares), followed by Kratos Defense & Security Solutions at $125.0M (1,773,655 shares) and Boeing at $122.8M (617,000 shares).
• · The smallest positions by value are iShares China Large-Cap ETF ($4.5M), Bullish Ord Shs ($7.2M), and DBX ETF Trust Xtrackers Harvest CSI 300 ($8.2M).
• · The portfolio includes exposure to technology (NVIDIA, Interactive Brokers), defense (Kratos, Boeing), digital assets (Galaxy Digital, Bullish), and Chinese equities (Alibaba, KE Holdings, H World Group, iShares China ETF, DBX CSI 300 ETF).
• · No period-over-period comparison is possible as this appears to be an initial filing or the prior period data is not included in this extract.

19-05-2026

Blackstone Mortgage Trust, Inc. (BXMT) completed a $450M offering of 6.250% Senior Secured Notes due 2031 on May 19, 2026. The notes are secured on a first-priority basis by substantially all assets of the company and its guarantors, and proceeds will be used for general corporate purposes including paying down existing secured debt. The issuance increases the company's leverage and interest expense, but provides liquidity for refinancing.

• · The notes were issued in a private offering under Rule 144A and Regulation S.
• · Interest is payable semi-annually on June 1 and December 1, commencing December 1, 2026.
• · The notes mature on June 1, 2031.
• · Optional redemption before March 1, 2031 requires a make-whole premium; on or after that date, redemption is at par plus accrued interest.
• · Up to 40% of the notes can be redeemed before December 1, 2027 using proceeds from certain equity offerings at a price of 106.250%.
• · A change of control triggering event requires the company to offer to repurchase notes at 101% of principal plus accrued interest.
• · The notes are senior secured obligations ranking pari passu with existing First Lien Obligations, including the Term Loan Credit Agreement and the 3.750% and 7.750% Senior Secured Notes.
• · The notes are secured by substantially all assets of the company and guarantors on a first-priority basis, subject to a first lien intercreditor agreement dated October 5, 2021.
• · Upon a Collateral Fall-Away Event, the notes become unsecured.
• · Covenants include a maximum Total Debt to Total Assets Ratio of 83.333% before a Collateral Fall-Away Event and a minimum Total Unencumbered Assets to Total Unsecured Indebtedness Ratio of 1.20 to 1.00 after.
• · The indenture includes events of default that could accelerate repayment of all outstanding notes.

19-05-2026

IRIDEX CORP reported net loss of $524K for Q1 FY26 (three months ended April 4, 2026), a significant improvement from a $1,686K net loss in the same prior-year period, driven by a sharp reduction in other expenses ($142K vs. $1,469K). However, total revenues declined slightly by 0.8% to $11,799K from $11,896K year-over-year, with gross profit also falling from $5,055K to $4,741K as cost of revenues increased, and cash used in operations deepened to $1,335K from $1,149K, reflecting a weak operating cash flow trend.

• · Gross margin contracted to 40.2% in Q1 FY26 from 42.5% in the prior-year period, reflecting higher costs.
• · Operating expenses decreased 3.7% YoY, driven by a 16% reduction in G&A ($1,623K vs. $1,931K), while R&D and sales & marketing increased modestly.
• · Cash used in operating activities deepened to $1,335K in Q1 FY26 from $1,149K in Q1 FY25, primarily due to inventory build of $1,448K.
• · Total deferred revenue at the end of Q1 FY26 was $8,462K, down from $10,058K at the end of the prior-year period, indicating a declining backlog.
• · Working capital decreased to $11,756K (current assets of $24,584K minus current liabilities of $12,828K) from $12,044K at the start of the fiscal year.
• · Stockholders' equity declined to $4,732K from $4,922K at January 3, 2026.
• · No new debt or equity was raised in Q1 FY26, compared to $4,000K from a convertible note and $6,000K from Series B preferred in the prior-year period.

19-05-2026

Einride AB and Legato Merger Corp. III announced that the SEC declared effective the Registration Statement on Form F-4 for their proposed business combination, with an Extraordinary General Meeting of Legato shareholders scheduled for June 4, 2026 to approve the transaction. The deal values Einride at a pre-money equity value of $1.35 billion and is expected to deliver approximately $300 million in gross proceeds, including a $113 million oversubscribed PIPE capital raise. The combined company will trade on Nasdaq under the ticker symbol 'ENRD'.

• · Extraordinary General Meeting of Legato shareholders to approve the transaction is scheduled for June 4, 2026 at 10:00 am ET.
• · Shareholders of record as of May 7, 2026 are eligible to vote.
• · The definitive proxy statement/prospectus was filed with the SEC on May 15, 2026.
• · The business combination agreement was announced on November 12, 2025.
• · Einride was founded in 2016 and operates digital, electric and autonomous freight solutions across North America, Europe and the Middle East.
• · Legato Merger Corp. III is a blank check company organized for business combination purposes.

19-05-2026

Home Depot reported Q1 FY2026 Q1 sales rose 4.8% YoY to $41.8B, driven by a 0.6% increase in comparable sales and a 2.2% rise in average ticket. However, net earnings declined 4.2% YoY to $3.3B, and diluted EPS fell 4.3% to $3.30, as operating margin contracted 100 bps to 11.9%. The company reaffirmed its FY2026 guidance, including total sales growth of 2.5%-4.5% and flat to 2.0% comparable sales growth.

• · Foreign exchange rates positively impacted total company comparable sales by approximately 55 basis points.
• · Gross margin declined to 33.0% from 33.8% in the prior year quarter.
• · Operating margin contracted 100 bps to 11.9% (GAAP); adjusted operating margin was 12.3% vs 13.2%.
• · The company operated 2,361 retail stores and over 1,280 SRS locations at quarter end.
• · Cash provided by operations was $6.0B, up from $4.3B in the prior year quarter.
• · Capital expenditures were $844M in Q1.
• · The company paid $2.3B in cash dividends during the quarter.
• · FY2026 guidance includes: total sales growth ~2.5%-4.5%, comparable sales growth ~flat to 2.0%, ~15 new stores, gross margin ~33.1%, operating margin ~12.4%-12.6%, adjusted operating margin ~12.8%-13.0%, effective tax rate ~24.3%, net interest expense ~$2.3B, diluted EPS growth flat to 4.0% from $14.23, adjusted diluted EPS growth flat to 4.0% from $14.69, capex ~2.5% of sales.

19-05-2026

InMed Pharmaceuticals entered into an amending agreement with Armistice Capital Master Fund Ltd. to reduce the exercise price of outstanding preferred investment options from $16.60 to $0.80 per common share, covering up to 278,761 common shares. The amendment significantly lowers the conversion threshold for Armistice, potentially leading to future dilution for existing shareholders, but no assurance is a necessary step to maintain financing flexibility given the company's current stock price.

• · The original exercise price was $16.60 per share, set in October 2023.
• · The amended exercise price is $0.80 per share, a 95.2% reduction.
• · The options were issued in a private placement under Section 4(a)(2) of the Securities Act and Regulation D.
• · No assurance is given that any of the options will be exercised.
• · InMed's pipeline includes programs for Alzheimer's, ocular, and dermatological indications.

19-05-2026

Seven Six Capital Management, LLC filed its quarterly 13F-HR for the period ending March 31, 2026, disclosing 25 equity holdings with a total market value of approximately $92.98 million. The portfolio is concentrated in mid-cap value and special situation names, with top positions in Boyd Gaming ($10.3M), Amcor PLC ($8.9M), and Graphic Packaging ($5.8M). The filing shows a diversified mix across gaming, packaging, transportation, and consumer discretionary sectors, but no prior quarter comparison is available to assess turnover or performance trends.

• · The filing was signed by Matthew Weissman, CFO/COO, on May 15, 2026.
• · All 25 positions are held with sole voting and dispositive power; no shared or non-voting positions reported.
• · Smallest position by market value: Janus International Group ($602,550).
• · Smallest position by share count: ArcBest Corp (42,608 shares).
• · Sector exposure includes gaming (Boyd, Penn), packaging (Amcor, Crown, Graphic Packaging), automotive (Asbury, Stellantis, Whirlpool), and food service (Dine Brands, Jack in the Box, Lamb Weston).

19-05-2026

AlphaVest Acquisition Corp. reported a net income of $145,601 for Q1 2026, reversing a net loss of $77,177 in Q1 2025. However, total revenues declined 33.9% to $1,184,616 from $1,792,525, driven by a sharp drop in product revenue. Cash and cash equivalents decreased to $6,632,619 from $7,004,601 at year-end 2025.

• · Gross profit improved to $1,020,656 from $488,330, a 109% increase.
• · Operating income was $128,539 compared to an operating loss of $747,753.
• · Total operating expenses decreased 27.8% to $892,117 from $1,236,083.
• · Cash used in operating activities was $391,580 vs. cash provided of $203,985 in prior year.
• · Accounts receivable - related party increased to $3,114,877 from $2,065,890.
• · Inventories decreased to $914,678 from $1,069,465.
• · Accumulated deficit improved to $27,192,508 from $27,338,109.

19-05-2026

Bridgeline Digital reported Q2 FY2026 revenue of $3.9M, flat YoY, and subscription revenue of $3.1M, also flat YoY. However, the company achieved record new customer wins with 19 new subscription contracts totaling $2.8M in total contract value and $875K in annual recurring revenue, while core subscription ARR per new customer doubled to $44,000 from $21,000. Net loss improved to $0.4M from $0.7M in the prior year period, but gross margin declined to 64% from 68%.

• · Core revenue grew to 61% of total revenue and 65% of subscription revenue, both increasing from prior quarter and prior year.
• · Subscription revenue as a percentage of total revenue improved to 80% from 79% YoY.
• · Services gross margin declined to 47% from 52% YoY.
• · Operating expenses decreased 11.8% YoY to $3.0M.
• · HawkSearch received multiple 2026 honors from Info-Tech Research Group including Leader in Enterprise Search.
• · A leading global gas provider selected HawkSearch for a technically complex multi-lingual, multi-site implementation.
• · A wholesale distributor selected HawkSearch across five sites on OroCommerce with potential expansion to eight sites.
• · A national industrial supplier selected HawkSearch for specification-driven catalog search.
• · An Australia-based global electrical wholesaler selected HawkSearch with expansion potential to a second website.
• · A leading home décor brand selected HawkSearch for four ecommerce sites, originated through a customer referral.
• · Barron Designs and AZ Faux, serving 270,000 monthly visitors, selected HawkSearch.
• · A leading industrial distributor, first Unilog customer using HawkSearch connector, selected after proof-of-concept.
• · Precision metalworking manufacturer with 80+ years heritage selected HawkSearch for WooCommerce platform.

19-05-2026

Catholic Responsible Investments Funds (CRI) filed a DEFA14A on May 19, 2026, seeking shareholder approval to transition the CRI Small-Cap Fund from a passively managed small-cap strategy to an actively managed small- and mid-cap (SMID) strategy with a multi-manager structure. The filing contains no financial data or period-over-period comparisons, only a strategic proposal aimed at pursuing diversified alpha sources and stronger long-term outcomes for Catholic investors.

• · The filing is a DEFA14A (definitive additional proxy materials) filed on May 19, 2026.
• · The proposal introduces a multi-manager structure for the Small-Cap Fund.
• · The fund currently follows a passively managed small-cap strategy.
• · The proposed strategy expands to small- and mid-cap (SMID) stocks.
• · CBIS believes small-cap and SMID markets reward skilled active management.
• · No financial figures, performance data, or period-over-period comparisons are included in the filing.

19-05-2026

Aramco and Pasqal have launched Saudi Arabia's first quantum computer and the Middle East's first commercial Quantum Computing as a Service (QCaaS) platform, located at Aramco's data center in Dhahran. The Pasqal Quantum Processing Unit (QPU), deployed in November 2025, controls 200 programmable qubits and is now entering active operation. The announcement also highlights Pasqal's planned Nasdaq listing via a business combination with Bleichroeder Acquisition Corp. II (Nasdaq: BBCQ).

• · Pasqal was founded in 2019 and has raised over USD 500M in total funding.
• · Pasqal employs over 275 people and serves over 25 clients and partners.
• · The QPU was first deployed in November 2025 and is now entering active operation.
• · Wa'ed Ventures initially invested in Pasqal in January 2023.
• · Aramco workstreams include port logistics optimization, CO₂ storage optimization, well placement, rig scheduling, and quantum workforce building.
• · Pasqal is pursuing a Nasdaq listing via a business combination with Bleichroeder Acquisition Corp. II (Nasdaq: BBCQ).

19-05-2026

Ambow Education Holding Ltd. (NYSE American: AMBO) announced the launch of the HybriU Collaboration Board, a new AI-powered phygital product that enables real-time interactive whiteboard collaboration via a single QR code scan, with no software installation or account creation required. The product is available immediately globally and targets corporate meetings, classrooms, workshops, and live events. No financial figures or performance metrics were disclosed in this filing.

• · The HybriU Collaboration Board supports multi-format content including PDFs, PowerPoint presentations, images, sketches, and drawings.
• · Participants can join from any device with a single QR code scan; no software installation or account creation is required.
• · The product is available immediately starting May 19, 2026, through www.hybriu.com/products/collaboration-board.
• · The filing contains no financial data, revenue figures, or performance metrics.

19-05-2026

Civista Bancshares, Inc. held its Annual Meeting on May 19, 2026, and furnished presentation materials via an 8-K filing. The company is a $4.3 billion financial holding company headquartered in Sandusky, Ohio, operating 44 locations across Ohio, Southeastern Indiana, and Northern Kentucky. No specific financial results or performance metrics were disclosed in the filing.

• · Civista Bank was founded in 1884.
• · The company's common shares trade on the NASDAQ Capital Market under the symbol 'CIVB'.
• · The presentation material is attached as Exhibit 99.1 and is furnished under Regulation FD.

19-05-2026

Live Oak Bancshares declared a $0.03 per share dividend on common stock and a $0.52344 per depositary share dividend on its Series A preferred stock, payable June 15, 2026 to shareholders of record as of June 2, 2026. No period-over-period comparisons are available as this is a one-time declaration.

• · Dividend record date is June 2, 2026.
• · Dividend payment date is June 15, 2026.
• · Preferred stock dividend rate is 8.375% fixed.

19-05-2026

FB Bancorp, Inc. (FBLA) announced on May 19, 2026 the completion of its second stock repurchase program, under which it repurchased 1,785,375 shares (10% of outstanding) at an average price of $13.717 per share inclusive of costs. The buyback represents a significant capital return to shareholders, but the average repurchase price reflects the prevailing market level at the time of execution.

19-05-2026

Bitcoin Depot Inc. received a Nasdaq delisting notice on May 18, 2026, following its Chapter 11 bankruptcy filing on May 17, 2026, and failure to timely file its Form 10-Q for the period ended March 31, 2026. Trading of the company's Class A common stock and warrants will be suspended at the opening of business on May 26, 2026, and a Form 25-NSE will be filed to remove the securities from listing and registration. The company does not intend to appeal Nasdaq's determination, and it cautions that holders of its securities could experience a significant or complete loss on their investment.

• · The delisting is based on Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1 due to the Chapter 11 filing, and also on failure to timely file Form 10-Q for the period ended March 31, 2026 (Nasdaq Listing Rule 5250(c)).
• · The company's warrants have an exercise price of $80.50 per share.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.

19-05-2026

The Federal Home Loan Bank of New York issued two consolidated obligations on May 14, 2026, with a total par value of $26,500,000. The first is a $10,000,000 callable bond (CUSIP 3130BAS24) with a 4% coupon, maturing November 19, 2027, and redeemable on a Bermudan call schedule starting November 19, 2026. The second is a $16,500,000 non-callable fixed-rate bond (CUSIP 3130BASC2) with a 3.85% coupon, maturing January 6, 2028. Both bonds are fixed-rate constant obligations, representing routine funding activities with no unusual terms or negative features.

• · Trade date for both bonds: May 14, 2026.
• · Settlement date for callable bond: May 19, 2026; for non-callable bond: May 18, 2026.
• · Next pay date for callable bond: November 19, 2026; non-callable bond: January 6, 2028.
• · Callable bond has a Bermudan call style, redeemable on specified recurring dates starting November 19, 2026.
• · Non-callable bond has no call feature (Non-Callable).
• · Both bonds are Fixed Constant rate type/subtype.

19-05-2026

Bausch Health Companies Inc. held its Annual Meeting on May 19, 2026, where shareholders elected all 10 director nominees, including new director Eiry W. Roberts, M.D., and approved executive compensation on a non-binding advisory basis. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the upcoming fiscal year.

• · All director nominees received substantial support, with 'For' votes ranging from approximately 183.9 million to 197.0 million shares.
• · The advisory vote on executive compensation passed with approximately 189.4 million 'For' votes, 9.6 million 'Against', and 537,614 abstentions.
• · The appointment of PricewaterhouseCoopers LLP as auditor was ratified with approximately 276.8 million 'For' votes and 2.6 million 'Withheld'.
• · Broker non-votes were approximately 79.9 million for each director election and the compensation vote, but not applicable for the auditor ratification.

19-05-2026

Farmer Mac completed the issuance of 4,000,000 shares of 6.875% Non-Cumulative Preferred Stock, Series I, in an exempt public offering on May 19, 2026. The offering was made pursuant to an underwriting agreement dated May 12, 2026, with Morgan Stanley & Co. LLC as representative of the underwriters. No financial results or period-over-period comparisons are included in this filing.

• · The offering was exempt and made pursuant to an offering circular.
• · The underwriting agreement was dated May 12, 2026.
• · The filing does not include any financial statements or period-over-period comparisons.

19-05-2026

Eastern Bankshares, Inc. held its 2026 annual meeting on May 18, 2026, where shareholders elected six directors, approved advisory executive compensation, and ratified Ernst & Young LLP as auditor for fiscal 2026. All director nominees received strong support, with votes for ranging from 163.2M to 172.8M, though Luis A. Borgen received the highest against votes (11.5M) and abstentions (8.2M). The advisory say-on-pay vote passed with 172.9M for and 8.8M against, while auditor ratification saw 191.5M for and 12.6M against.

• · Broker non-votes totaled 21,797,754 on director elections and the advisory compensation vote.
• · Luis A. Borgen received the lowest votes for (163,246,719) and highest votes against (11,536,334) among director nominees.
• · Ratification of Ernst & Young LLP had no broker non-votes, with 191,474,469 votes for, 12,617,770 against, and 697,048 abstentions.
• · Advisory vote on executive compensation had 1,244,798 abstentions.

19-05-2026

Ardelyx, Inc. filed a DEFA14A additional proxy soliciting material on May 19, 2026, referencing forward-looking statements originally filed with the SEC on April 30, 2026. The filing contains no new financial data or operational updates, only standard cautionary language regarding forward-looking statements and the company's disclaimers of any obligation to update them.

• · The filing is a DEFA14A (additional definitive proxy soliciting material) filed on May 19, 2026.
• · The content references forward-looking statements originally filed with the SEC on April 30, 2026.
• · The filing includes standard cautionary language that actual results could differ materially from forward-looking statements.
• · Ardelyx undertakes no obligation to update forward-looking statements except as required by law.

19-05-2026

Teradata Corporation held its Annual Meeting on May 14, 2026, with 93.33% of outstanding shares represented. Stockholders approved the Amended 2023 Stock Incentive Plan (adding 6.3M shares), elected three Class I directors (Melissa B. Fisher, Stephen McMillan, Kimberly K. Nelson), passed the say-on-pay advisory vote, and ratified PwC as auditor for 2026. While all proposals passed, director Kimberly K. Nelson received a notable 9.6% against vote (7.67M shares), and the Amended 2023 Plan saw 8.0% against votes (6.4M shares), indicating some shareholder dissent.

• · Say-on-pay advisory vote passed with 77,550,609 For vs 2,479,139 Against (96.9% approval among votes cast, excluding broker non-votes).
• · Ratification of PwC as auditor passed overwhelmingly with 87,449,014 For vs 638,248 Against (99.3% approval).
• · Broker non-votes totaled 8,096,976 on all director elections and the say-on-pay and plan proposals.
• · The Amended 2023 Plan adds 6.3M shares to the existing plan, increasing total authorized shares.

19-05-2026

Stellar Bancorp, Inc. is urging shareholders to take immediate action regarding their investment(s) ahead of a May 26, 2026 deadline, in connection with the proposed acquisition by Prosperity Bancshares, Inc. The transaction, which involves the issuance of Prosperity common stock to Stellar shareholders, is subject to shareholder approval and other closing conditions. While the filing highlights the need for shareholder participation, it also outlines significant risks, including potential failure to obtain shareholder approval, integration challenges, and dilution from the issuance of additional shares.

• · The definitive proxy statement/prospectus was mailed to Stellar shareholders on April 23, 2026.
• · The Registration Statement on Form S-4 (File No. 333-294882) was declared effective on April 21, 2026.
• · Shareholders are asked to contact Georgeson LLC toll-free at (888) 463-8808 before May 26, 2026.
• · Risks include failure to obtain necessary shareholder approval, integration difficulties, and dilution from the issuance of additional Prosperity common stock.
• · The filing does not provide any financial figures or performance metrics for Stellar Bancorp.

19-05-2026

Intercontinental Exchange, Inc. held its Annual Meeting on May 15, 2026, where shareholders elected eleven directors, approved executive compensation on an advisory basis, approved amendments to the certificate of incorporation for regulatory compliance, ratified Ernst & Young as auditor, and did not approve a stockholder proposal for an independent board chairman. All director nominees received majority support, but some faced significant opposition, with Caroline L. Silver and Jeffrey C. Sprecher receiving over 20 million votes against.

• · Record date for voting was March 19, 2026.
• · Broker non-votes totaled 29,338,574 on all director elections and most proposals.
• · Ratification of auditor received 478,979,319 for, 31,109,563 against, and 2,043,221 abstain.
• · Stockholder proposal for independent board chairman received 114,294,843 for, 365,598,810 against, and 2,899,876 abstain.

19-05-2026

NBT Bancorp Inc. held its Annual Meeting on May 19, 2026, where all 12 director nominees were elected, the compensation of named executive officers was approved in a non-binding advisory vote (34,610,946 for, 1,018,485 against), and the appointment of KPMG LLP as independent auditor for fiscal 2026 was ratified (41,843,242 for, 445,896 against). Additionally, the Board approved a second-quarter 2026 cash dividend of $0.37 per share, payable June 15, 2026 to shareholders of record on June 1, 2026. While all proposals passed, the advisory vote on executive compensation saw notable opposition (1,018,485 votes against, 319,537 abstentions), and director V. Daniel Robinson, II received the highest number of votes against (1,443,125) among nominees.

• · The annual meeting was held on May 19, 2026.
• · All director nominees were elected with votes for ranging from 34,440,287 (V. Daniel Robinson, II) to 35,677,992 (J. David Brown).
• · V. Daniel Robinson, II received the highest number of votes against (1,443,125) among director nominees.
• · Timothy E. Delaney had the highest number of abstentions (125,828) among director nominees.
• · The advisory vote on executive compensation had 34,610,946 votes for, 1,018,485 against, and 319,537 abstentions.
• · Ratification of KPMG as auditor had 41,843,242 votes for, 445,896 against, and 194,440 abstentions.
• · The second-quarter 2026 cash dividend of $0.37 per share will be paid on June 15, 2026 to shareholders of record on June 1, 2026.
• · The definitive proxy statement was filed with the SEC on April 6, 2026.

19-05-2026

Transcat, Inc. approved a compensation increase for Chief Operating Officer Michael W. West, effective March 29, 2026, for fiscal year 2027. The new package includes a base salary of $425,000 per annum, a target cash incentive of 40% of base salary, and a target long-term equity incentive of 65% of base salary. No prior-period compensation data is provided for comparison.

• · Compensation approved by Compensation Committee of the Board on May 13, 2026.
• · Filing date is May 19, 2026.
• · No prior compensation figures for Mr. West are disclosed, preventing period-over-period comparison.

19-05-2026

Western Wealth Management, LLC filed its quarterly 13F-HR for the period ending March 31, 2026, reporting total holdings of approximately $2.737 billion across 3,051 positions. The portfolio is heavily concentrated in mega-cap technology stocks, with Apple Inc. ($88.5M), Amazon.com Inc. ($39.4M), and Alphabet Inc. (combined Class A and C, ~$48.4M) representing the largest equity holdings. The filing shows a diversified mix of equities, ETFs, and options, with notable positions in Amplify ETFs (e.g., Amplify Junior Silver Mine ETF at $3.74M) and Ares Capital Corp ($1.39M).

• · The filing includes options positions: a call option on Advanced Micro Devices Inc. (25 shares, $161,750 value) and a put option on AT&T Inc. (10 shares, $20 value).
• · The portfolio holds a significant number of ETF positions, including multiple Amplify ETFs (e.g., Amplify Junior Silver Mine ETF at $3.74M, Amplify Blockchain Technology ETF at $1.26M) and American Century ETFs (e.g., US Small Cap Value ETF at $2.20M, US Large Cap Value ETF at $1.60M).
• · Notable smaller positions include AST SpaceMobile Inc. ($825,469), Aurora Innovation Inc. ($249,587), and Aurinia Pharmaceuticals Inc. ($301,098).
• · The filing does not provide period-over-period comparisons, so no trends or changes in holdings can be assessed.

19-05-2026

Farmers & Merchants Bancshares, Inc. (FMFG) announced a cash dividend of $0.36 per share on its common stock, declared by the Board on May 18, 2026. The dividend will be paid on June 18, 2026 to stockholders of record as of June 2, 2026. No prior-period dividend data is provided, so no period-over-period comparison is possible.

• · Dividend record date: June 2, 2026
• · Dividend payment date: June 18, 2026
• · Press release dated May 19, 2026 filed as Exhibit 99.1

19-05-2026

Cathay General Bancorp held its 2026 Annual Meeting on May 18, 2026, where stockholders elected all four Class III director nominees, approved executive compensation on an advisory basis, and ratified KPMG LLP as the independent auditor for fiscal 2026. Shareholders also expressed a preference for an annual advisory vote on executive compensation, which the Board adopted until the next required vote in 2032. While all proposals passed, director nominees Nelson Chung and Richard Sun received notable opposition, with over 3.5 million and 3.8 million votes against, respectively.

• · The record date for voting was March 26, 2026.
• · Broker non-votes totaled 6,966,519 on all director elections and advisory proposals.
• · The advisory vote on executive compensation passed with 47,296,739 for, 1,061,747 against, and 283,341 abstentions.
• · The frequency vote showed 44,241,623 for every year, 72,326 for every other year, 4,030,739 for every three years, and 297,139 abstentions.
• · Ratification of KPMG LLP received 54,781,568 for, 754,933 against, and 71,845 abstentions (no broker non-votes).
• · The next required vote on the frequency of advisory executive compensation votes will be at the 2032 annual meeting.

19-05-2026

Claros Mortgage Trust, Inc. filed a DEFA14A proxy statement for its 2026 Annual Meeting to be held virtually on June 3, 2026. The board recommends voting for the election of nine director nominees, ratification of PricewaterhouseCoopers as auditor, advisory approval of executive compensation, and approval of an amendment to the 2016 Incentive Award Plan. No financial results or performance metrics are included in this filing.

• · Annual Meeting date: June 3, 2026 at 1:00 p.m. Eastern Daylight Time
• · Virtual meeting link: www.virtualshareholdermeeting.com/CMTG2026
• · Voting deadline: June 2, 2026 at 11:59 PM ET
• · Proxy materials available at www.proxyvote.com
• · Paper/email copy request deadline: May 20, 2026

19-05-2026

Vistagen Therapeutics appointed Dr. Angel S. Angelov as Chief Medical Officer effective May 18, 2026. Dr. Angelov brings over 20 years of experience from Karuna, Neurocrine, Novartis, and Teva. He received an inducement option to purchase 150,000 shares at $0.5955 per share, vesting over four years.

• · Dr. Angelov is Board Certified in Psychiatry and holds an active Pennsylvania medical license.
• · The option vests 25% on the one-year anniversary, then ratably monthly over 36 months.
• · Vistagen's pherine candidates are designed to avoid blood absorption or brain uptake.

19-05-2026

Ranger Energy Services held its 2026 Annual Meeting on May 15, 2026, with 20,622,930 of 23,910,765 eligible shares represented. Stockholders reelected Stuart N. Bodden and Sean Woolverton as Class II directors, ratified Grant Thornton LLP as the independent auditor for FY 2026, and approved — on a non-binding advisory basis — the company's executive compensation program.

• · Voter turnout was 86.2% of eligible shares (20,622,930 of 23,910,765).
• · Proposal 1: Both director nominees received substantial withhold votes (Bodden: 5,596,084; Woolverton: 5,861,233), representing 36.3% and 38.0% of votes cast (excluding broker non-votes), respectively.
• · Proposal 2: Auditor ratification passed overwhelmingly with 20,597,749 FOR votes (99.9% of votes cast), only 12,926 AGAINST and 12,255 WITHHOLD.
• · Proposal 3: Non-binding advisory vote on executive compensation passed with 15,188,844 FOR votes (98.6% of votes cast excluding broker non-votes), but 186,977 voted AGAINST.
• · Broker non-votes on director election and say-on-pay proposals totaled 5,211,420 shares (25.3% of represented shares).

19-05-2026

Eton Pharmaceuticals entered into a supply and distribution agreement for exclusive U.S. commercialization rights to IMPAVIDO® (miltefosine), an FDA-approved orphan drug for leishmaniasis, from an affiliate of Knight Therapeutics. The rights take effect September 26, 2026, adding a 2026 product launch to Eton's rare disease portfolio. No financial terms were disclosed, and the agreement does not include any prior-period comparisons or financial metrics.

• · IMPAVIDO® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species.
• · Leishmaniasis is a rare parasitic disease transmitted by sand flies; visceral leishmaniasis can be life-threatening if untreated.
• · IMPAVIDO® has been commercially available in the United States since 2016.
• · Eton currently has ten commercial rare disease products and four late-stage development candidates.
• · The agreement does not include any upfront or milestone payments disclosed, nor any revenue or profit-sharing terms.

19-05-2026

CNS Pharmaceuticals filed an S-3 registration statement to register up to 9,793,479 shares of common stock for resale by selling shareholders, including 650,000 outstanding shares and 9,143,479 shares issuable upon exercise of pre-funded warrants. The company will not receive any proceeds from share sales by selling shareholders and will only receive nominal proceeds (maximum $9,143.48) from cash exercises of the pre-funded warrants. The offering represents significant dilution relative to the 1,461,449 shares outstanding as of May 14, 2026, and the company warns that resales could adversely affect the market price of its common stock.

• · The Pre-Funded Warrants have no expiration date and are exercisable at a nominal exercise price of $0.001 per share.
• · The Pre-Funded Warrants are exercisable on a cashless basis, so the company may receive little or no cash proceeds.
• · Selling shareholders are subject to a 4.99% or 9.99% beneficial ownership limitation on exercise of Pre-Funded Warrants.
• · The company's common stock is listed on Nasdaq Capital Market under symbol 'CNSP'; Pre-Funded Warrants will not be listed.
• · Outstanding warrants have a weighted average exercise price of $90.72 per share, and outstanding options have a weighted average exercise price of $3,289.55 per share.
• · The registration statement incorporates by reference the Annual Report on Form 10-K for the year ended December 31, 2025, and the Quarterly Report on Form 10-Q for the period ended March 31, 2026.

19-05-2026

Oramed Pharmaceuticals reported a net income of $38.3M for Q1 2026, a significant turnaround from a net loss of $7.6M in Q1 2025, driven by $44.8M in financial income and $8.3M in other income. However, the company had zero revenue in Q1 2026 compared to $2.0M in Q1 2025, and operating loss improved only modestly to $3.7M from $4.5M. Cash and cash equivalents dropped sharply to $13.2M from $45.9M at year-end 2025, largely due to $11.9M in Lifeward transactions and $10.4M in dividend payments.

• · The company held $102.3M in investment in associate at fair value as of March 31, 2026, up from $71.6M at year-end 2025.
• · Deferred tax liabilities increased to $17.7M from $7.9M at December 31, 2025.
• · Basic earnings per share were $0.94 in Q1 2026 versus a loss of $0.19 in Q1 2025.
• · Weighted average diluted shares outstanding were 41,970,186 in Q1 2026, up from 41,228,782 in Q1 2025.
• · The company recognized a $5.8M gain on sale of IP in Q1 2026.
• · Net cash used in operating activities was $2.9M in Q1 2026, compared to $3.5M in Q1 2025.
• · The company invested $11.9M in Lifeward transactions, acquiring 1,250,363 ordinary shares (45.0% stake) and 1,006,113 pre-funded warrants.
• · Dividends paid totaled $10.4M in Q1 2026.
• · Stock-based compensation was $1.7M in Q1 2026, down from $2.2M in Q1 2025.

19-05-2026

Federal Home Loan Bank of Dallas filed an 8-K disclosing the issuance of consolidated obligation bonds totaling $920 million across multiple trade dates in May 2026. The bonds include both fixed-rate callable bonds and a $500 million variable-rate floater tied to Overnight SOFR plus one basis point, with maturities ranging from 2026 to 2036. These obligations are joint and several with the other 11 FHLBanks and are not guaranteed by the U.S. government.

• · The $500 million variable-rate floater is tied to Overnight SOFR plus one basis point and matures on 8/21/2026.
• · All bonds are callable except the $500 million floater, which is non-callable.
• · The longest maturity is 10 years (5/21/2036) for two bonds totaling $25 million.
• · The largest single issuance is the $500 million floater, representing over 54% of total par amount.
• · Consolidated obligations are not guaranteed by the U.S. government and are backed only by the financial resources of the 11 FHLBanks.

19-05-2026

SunPower Inc. reported net income of $5.3M for Q1 2026, up from $4.8M in Q1 2025, driven by a sharp improvement in gross profit ($44.7M vs $27.4M) and a $30.8M gain in other non-operating income. However, revenue declined 7.2% to $72.8M, operating loss widened to $19.2M from $3.7M, and cash used in operations increased to $25.7M, reflecting deteriorating core operating performance.

• · Total stockholders' deficit improved to $61.5M from $90.1M at year-end 2025, primarily due to net income and equity issuances.
• · Goodwill increased to $75.6M from $62.6M, reflecting acquisition activity.
• · Short-term debt with third parties increased to $13.7M from zero, while short-term debt with related parties remained at $21.5M.
• · Contract liabilities (current) decreased sharply to $12.6M from $20.3M, indicating revenue recognition or fulfillment of obligations.
• · The company issued 4.56 million shares of common stock for $7.0M in cash proceeds during Q1 2026.
• · Interest expense rose to $6.9M from $6.0M, with related party interest and amortization of debt issuance costs of $2.3M.
• · Cash paid for interest increased to $5.3M from $1.4M in the prior year quarter.
• · The company recognized $3.3M in common stock as partial consideration for an acquisition and $6.3M in deferred consideration for the acquisition of Cobalt.
• · Basic EPS declined to $0.04 from $0.06 due to a 55% increase in weighted-average basic shares.
• · Sales commissions surged to $28.6M from $7.7M, a 272% increase, while sales and marketing expenses fell to $5.0M from $8.5M.

19-05-2026

U.S. Physical Therapy, Inc. held its Annual Meeting of Shareholders on May 19, 2026, where all three proposals were approved. All seven director nominees were elected, the advisory vote on executive compensation passed with 13,203,434 votes for and 894,885 against, and the ratification of Grant Thornton LLP as auditor was approved with 14,475,354 votes for. However, the say-on-pay proposal received a notable 6.3% against vote (894,885 votes), indicating some shareholder dissent on compensation.

• · Peter F. Minan received the highest votes for (14,005,301) and fewest votes withheld (102,931) among director nominees.
• · Christopher J. Reading received the most votes withheld (257,693) among director nominees.
• · Broker non-votes totaled 494,670 on the say-on-pay proposal.
• · The ratification of Grant Thornton LLP received 14,475,354 votes for, 126,323 against, and 1,225 abstentions.

19-05-2026

Bank First Corporation (BFC) announced a definitive agreement to merge with PSB Holdings, Inc. in an all-stock transaction valued at an exchange ratio of 0.3470 BFC shares per PSB share, with a potential downward adjustment if PSB's tangible book value is below $122.837 million. The merger is expected to close in Q4 2026, subject to shareholder and regulatory approvals. PSB directors and executive officers have entered into voting agreements in favor of the merger, and a side letter delays the closing to December 4, 2026, with a possible $1.00 per share special dividend for PSB shareholders if conditions are not met.

• · The merger consideration is subject to downward adjustment if PSB's tangible book value is less than $122,837,000 at closing.
• · PSB must pay a termination fee of $8,117,163 to BFC under certain circumstances, including if PSB accepts a superior proposal.
• · BFC will expand its board by one seat to appoint a PSB board member after closing.
• · The Side Letter Agreement delays closing to December 4, 2026, and allows PSB to pay a $1.00 per share special dividend if closing is delayed beyond that date due to conditions beyond PSB's fault.
• · The Merger Agreement includes customary representations, warranties, and covenants, and may be terminated if BFC's stock price declines more than 15% with a 15% greater decline than the NASDAQ Bank Index.